|

Sacituzumab Tirumotecan (sac-TMT) Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since June 2026

Also known as: MK-2870, SKB264

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC1
  • Fudan University1

Indications

  • Cancer2
  • Gastroesophageal Junction1
  • TNBC1
  • Gastroesophageal Adenocarcinoma1
  • Esophageal Neoplasms1

Other1 trial

Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
Phase 2

Tucson, Arizona1 trial

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.